PRECLINICAL REPORTSAnthraquinone antitumour agents, doxorubicin, pirarubicin and benzoperimidine BP1, trigger caspase-3/caspase-8-dependent apoptosis of leukaemia sensitive HL60 and resistant HL60/VINC and HL60/DOX cellsNowak, Robert; Tarasiuk, Jolanta Author Information Department of Biochemistry, University of Szczecin, Szczecin, Poland Correspondence to Jolanta Tarasiuk, Professor, Department of Biochemistry, University of Szczecin, 3c Felczaka St, 71-412 Szczecin, Poland Tel/fax: +48 91 444 1550; e-mail: [email protected] Received July 29, 2011 Accepted November 22, 2011 Anti-Cancer Drugs: April 2012 - Volume 23 - Issue 4 - p 380-392 doi: 10.1097/CAD.0b013e32834f8ab4 Buy Metrics Abstract We examined the effect of selected anthraquinone antitumour agents – doxorubicin (DOX), pirarubicin (PIRA) and benzoperimidine BP1 – on inducing apoptosis of the sensitive leukaemia HL60 cell line and its multidrug resistance sublines overexpressing P-glycoprotein (HL60/VINC) and multidrug resistance-associated protein 1 (HL60/DOX). All agents used at IC50 and IC90 were able to influence the cell cycle of sensitive HL60 and resistant cells and induce apoptosis. Interestingly, it was seen that HL60/VINC cells were more susceptible to undergo caspase-3/caspase-8-dependent apoptosis induced by the studied anthraquinone compounds compared with HL60 and HL60/DOX cells. However, the examined agents did not change the expression of Fas receptors on the surface of HL60-sensitive and-resistant cells. © 2012 Lippincott Williams & Wilkins, Inc.